Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer.

作者
Mitchell Parma,Eric Kumar Singhi,Luisa Maren Solis,Wei‐Lien Wang,Mehmet Altan,Maria Cecilia Franco-Vega,Alexa Halliday,João Gomes Jácome,Jianjun J. Zhang,John Victor Heymach,Lauren A. Byers,Carl Michael Gay,Bingnan Zhang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 8088-8088 被引量:7
标识
DOI:10.1200/jco.2025.43.16_suppl.8088
摘要

8088 Background: Tarlatamab, a bispecific T cell engager targeting Delta-Like ligand 3, received FDA approval in May 2024 for patients with relapsed extensive-stage small cell lung cancer (SCLC). While the clinical trials leading to its approval demonstrated impressive objective response, it has unique toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Here, we report a real-world case series of safety and efficacy data for patients treated with standard of care tarlatamab at MD Anderson Cancer Center. Methods: We queried the MD Anderson Lung Cancer GEMINI database for patients treated with tarlatamab and retrospectively collected demographic, clinical, and outcome data. From 7/1/2024-1/15/2025, a total of 39 patients received tarlatamab. 8 patients were excluded from analysis either due to diagnosis of extrapulmonary small cell cancer or rapid clinical deterioration due to disease progression around the time of the first tarlatamab infusion. The final cohort consisted of 31 patients. Results: The average age of our cohort was 66 years, 36% of patients were of non-white race, and their median lines of prior treatment was 2. 4 patients had transformed SCLC from classical EGFR-mutant lung adenocarcinoma (EGFR transformed), and 12 patients had untreated brain metastases (BM) prior to tarlatamab initiation. Safety data is summarized in the Table. At the cutoff, 17 patients had their first repeat systemic imaging: 59% had tumor shrinkage, 12% had stable or mixed tumor response, and 29% experienced tumor growth. Of the 3 EGFR transformed cases that had a repeat imaging on treatment, 2 had tumor growth. 18 patients underwent a repeat brain magnetic resonance imaging (MRI) after tarlatamab treatment. Out of 11 patients with untreated BM, 82% (9) had intracranial tumor shrinkage or stability, and 2 patients had mixed response, one of which was an EGFR transformed case. Of the 7 patients who either had no prior BM or had BM treated with radiation, only 1 had developed new BM (EGFR transformed). Conclusions: Preliminary data from this cohort show efficacy comparable to that observed in clinical trials. Notably, we report impressive intracranial response in patients with untreated BM. The toxicity profile reveals similar CRS but higher ICANS rates compared to those reported in the clinical trials. Additional data collection and analyses are ongoing at this time. Safety data from C1D1 and C1D8 of Tarlatamab. Adverse Event Hospitalization for C1D1 of Tarlatamab 1 mg IV (N=31) Hospitalization for C1D8 of Tarlatamab 10 mg IV (N=28) Cytokine-release syndrome – no. (%) Overall 12 (39) 11 (39) Grade 3 or more 1 (3) 1 (4) Tocilizumab Administration 8 (26) 4 (14) ICANS – no. (%) Overall 8 (26) 4 (14) Grade 3 or more 3 (10) 0 (0) Adverse event leading to ICU stay – no. (%) 4 (13) 1 (4)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
汉堡包的应助被白bai采纳,获得10
2秒前
3秒前
静jing发布了新的文献求助10
3秒前
Aster_Caelus关注了科研通微信公众号
3秒前
Maestro_S的应助被whx采纳,获得10
4秒前
鱼七发布了新的文献求助10
4秒前
4秒前
xx完成签到,获得积分0
4秒前
小胡完成签到,获得积分10
5秒前
5秒前
下隔热不完成签到 ,获得积分10
5秒前
young完成签到,获得积分10
6秒前
萨芬完成签到,获得积分10
6秒前
7秒前
7秒前
7秒前
邢智翔发布了新的文献求助10
7秒前
zhou发布了新的文献求助10
8秒前
8秒前
科研通AI6.3的应助被冰冰采纳,获得10
9秒前
9秒前
9秒前
fq完成签到 ,获得积分10
10秒前
11秒前
小马甲的应助被wms采纳,获得10
11秒前
HWX完成签到,获得积分10
12秒前
12秒前
炸薯条完成签到,获得积分10
13秒前
凡人修仙完成签到,获得积分10
13秒前
桐桐的应助被乔清采纳,获得10
13秒前
XIAOJU_U完成签到 ,获得积分10
14秒前
Aster_Caelus发布了新的文献求助10
15秒前
妖妖灵1111发布了新的文献求助10
15秒前
15秒前
Akim的应助被GBY采纳,获得10
17秒前
xi发布了新的文献求助10
17秒前
19秒前
公鸡下蛋发布了新的文献求助10
19秒前
daisylili完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177901
求助须知:如何正确求助?哪些是违规求助? 9568676
关于积分的说明 21800345
捐赠科研通 7772540
什么是DOI,文献DOI怎么找? 3432548
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478085